# Optimization of Therapeutic Human Serum Albumin Infusion in Selected Critically Ill Patients

> **NCT02755155** · PHASE4 · TERMINATED · sponsor: **University Hospital, Strasbourg, France** · enrollment: 138 (actual)

## Conditions studied

- Shock
- Systemic Inflammatory Response Syndrome (SIRS)
- Hypoalbuminaemia

## Interventions

- **DRUG:** Human serum albumin infusion 4%
- **DRUG:** Human serum albumin infusion 20%

## Key facts

- **NCT ID:** NCT02755155
- **Lead sponsor:** University Hospital, Strasbourg, France
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-09
- **Primary completion:** 2019-08-10
- **Final completion:** 2019-08-10
- **Target enrollment:** 138 (ACTUAL)
- **Why stopped:** too many patients were expected and the investigative team would not be able to recruit this number
- **Last updated:** 2021-09-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02755155

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02755155, "Optimization of Therapeutic Human Serum Albumin Infusion in Selected Critically Ill Patients". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02755155. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*